Mayinglong Pharmaceutical Group Co., Ltd. (600993.SS) — Stock Score Summary

Mayinglong Pharmaceutical Group Co., Ltd. (600993.SS) has a MoatMap StockRank of 86/100 based on Quality (79/100), Value (50/100), and Momentum (42/100) factor scores. The current signal is STRONG BUY. Mayinglong Pharmaceutical is a highly respected traditional Chinese medicine brand with a strong consumer moat. However, it lacks alignment with our active 18-month macro themes and faces localized regulatory risks.

Mayinglong Pharmaceutical Group Co., Ltd. is a renowned traditional Chinese medicine enterprise specializing in dermatological and hemorrhoidal treatments. The company holds an absolute dominant position in China's hemorrhoid treatment market, supported by its centuries-old brand heritage and proprietary formulas. Its strong brand equity and extensive retail pharmacy distribution network create an exceptionally deep competitive moat.

Key Financial Metrics

Price$3.45
Market Cap$1.5B
P/E (TTM)17.38
P/E (Forward)16.09
Price/Book2.23
Return on Equity13.5%
Return on Invested Capital15.3%
Debt/Equity2.21
Gross Margin48.7%
Operating Margin24.2%
Revenue Growth4.5%
Dividend Yield2.7%
Free Cash Flow$6M

Mayinglong Pharmaceutical Group Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Mayinglong Pharmaceutical Group Co., Ltd.’s (600993.SS) StockRank?
MoatMap’s StockRank for Mayinglong Pharmaceutical Group Co., Ltd. (600993.SS) is 86/100, with a Strong Buy signal. It is a composite of Quality (79), Value (50), and Momentum (42) factor ranks across MoatMap’s 19,000+ stock universe.
Does Mayinglong Pharmaceutical Group Co., Ltd. have an economic moat?
Mayinglong Pharmaceutical Group Co., Ltd. (600993.SS) has a Quality factor score of 79/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Mayinglong Pharmaceutical Group Co., Ltd. a buy, hold, or sell?
MoatMap’s current signal for Mayinglong Pharmaceutical Group Co., Ltd. (600993.SS) is Strong Buy, based on a StockRank of 86/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Mayinglong Pharmaceutical Group Co., Ltd. in?
Mayinglong Pharmaceutical Group Co., Ltd. (600993.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).
Browse all ranked stocks600993.SS deep dive reportAI ChampionsHow we score stocksSense-check another stock